Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
APT MedicalSHSE:688617 -1.35%78 EV-to-FCF is 38.59 as of Sep. 08, 2026, which is 61% below its 10-year median of 97.93. GuruFocus rates SHSE:688617 with a GF Score™ of 78/100 and a GF Value™ of ¥366.17 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 409 Medical Devices & Instruments companies, APT Medical ranks worse than 68.22% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, APT Medical's Enterprise Value is ¥32,995 Mil.
APT Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ¥855 Mil. Therefore, APT Medical's EV-to-FCF for today is 38.59.
The historical rank and industry rank for APT Medical's EV-to-FCF or its related term are showing as below:
SHSE:688617'
s EV-to-FCF Range Over the Past 10 Years
Min: 30.58 Med: 97.93 Max: 1274.32
Current: 38.05
During the past 9 years, the highest EV-to-FCF of APT Medical was 1274.32. The lowest was 30.58. And the median was 97.93.
SHSE:688617's EV-to-FCF is ranked worse than 68.22% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 23.9
vs SHSE:688617: 38.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
APT Medical's PE Ratio (TTM) for today is calculated as:
APT Medical's share price for today is ¥239.60.
APT Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥6.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
APT Medical EV-to-FCF Related Terms
APT Medical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for APT Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688617 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, APT Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
APT Medical EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, APT Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where APT Medical's EV-to-FCF falls into.
APT Medical's current Enterprise Value is ¥32,995 Mil.
APT Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥855 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APT Medical (SHSE:688617) has a EV-to-FCF of 38.59 as of Sep. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on APT Medical and its competitors. This is 61% below median its historical median of 97.93. Over the past decade, APT Medical's EV-to-FCF has ranged from 30.58 to 1,274.32. According to the industry distribution chart, APT Medical ranks #279 out of 409 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is APT Medical's EV-to-FCF too high?
APT Medical's current EV-to-FCF of 38.59 is 61% below median its 10-year median of 97.93. Over the past 10 years, this metric has ranged from a low of 30.58 to a high of 1,274.32. The Medical Devices & Instruments industry median EV-to-FCF is 23.90. APT Medical's value of 38.59 is 61.5% above this industry median. Based on the distribution chart, APT Medical ranks #279 out of 409 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, APT Medical has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does APT Medical's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, APT Medical ranks #279 out of 409 companies for EV-to-FCF. This places APT Medical in the lower half of its industry. The industry median EV-to-FCF is 23.90. APT Medical's value of 38.59 is 61.5% above this benchmark. Historically, APT Medical's own EV-to-FCF has ranged from 30.58 to 1,274.32 over the past decade. While the company's 10-year median is 97.93 vs. the industry median of 23.90, APT Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.90, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. APT Medical's current EV-to-FCF of 38.59 is 61.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on APT Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. APT Medical's current EV-to-FCF is 38.59, which is 61% below median its own 10-year median of 97.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is APT Medical stock overvalued right now?
Based on GuruFocus' analysis, APT Medical (SHSE:688617) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥366.17, compared to a current price of ¥239.60 — trading 34.6% below its estimated fair value. The current EV-to-FCF is 38.59, which is 61% below median its 10-year median of 97.93 and 61.5% above the Medical Devices & Instruments industry median of 23.90. APT Medical's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For APT Medical (SHSE:688617), the current EV-to-FCF is 38.59 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is APT Medical (SHSE:688617) Overvalued in 2026?
Based on GuruFocus' analysis, APT Medical stock appears to be undervalued.
The current stock price of ¥239.60 is trading 34.6% below its estimated GF Value™ of ¥366.17.
GuruFocus considers APT Medical to be Significantly Undervalued.
Key valuation signals for SHSE:688617:
EV-to-FCF: 38.59 (61% below median its 10-year median of 97.93)
GF Value™: ¥366.17 vs. price of ¥239.60 (34.6% below fair value)
Industry Position: 61.5% above the Medical Devices & Instruments median (#279 of 409)
No single metric tells the full story. See the SHSE:688617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
APT Medical Inc is engaged in the research and development, production and sales of electrophysiological and vascular interventional medical devices for cardiovascular and cerebrovascular diseases. Its products are sold in Europe, Eastern Europe, Southeast Asia and other countries and other regions.
78GF Score
Get the complete analysis for SHSE:688617
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688617 has been successfully added to your 
